BRCA1 and neoplasm: The identification of this pathogenic mutation, found only in the tumor sample, confirms the value of testing for tumor BRCA1/2 mutations, and identifies patients with germline and somatic BRCA mutations who may be eligible for treatment with PARP inhibitor drugs such as olaparib.